CVMCEL-SCI Corporation
The schedule
- Thu15Oct
Potential receipt of a Nasdaq deficiency notice as shares drift below the $1.00 compliance threshold.
- Sun15Nov
Crucial regulatory update on the submission status of the BLA for Multikine.
- Sun6Dec
Upcoming data presentation at ASCO covering Multikine updates.
- Wed20Jan
Proxy filing and shareholder vote to authorize a reverse stock split to regain Nasdaq compliance.
- Fri12Feb
Notification from the FDA regarding the acceptance of the BLA for formal review.
- Mon15Feb
- Mon17May
Fiscal Q4 2026 earnings release detailing commercialization readiness or further trial funding needs.
- Mon16Aug
Past
- Thu27Aug
Anticipated equity offering or toxic convertible debt issuance to fund ongoing operations and regulatory submissions.
- Mon17Aug
Release of Q2 2026 financial results with a critical focus on cash runway and capital preservation.
- Thu14May
Actual outcome: Bull · $1.43 at outcome
CEL-SCI reported Q2 EPS of -$0.68, which was exactly in line with estimates. The stock rallied 10% as the company successfully addressed critical cash runway concerns by closing a public offering just prior to earnings, while also securing a strategic agreement with Amarox for the commercialization of Multikine in Saudi Arabia. These developments provided much-needed capital and a clear commercial path for its lead asset, driving positive sentiment despite the ongoing R&D burn.
CEL-SCI reports Q2 earnings with a critical focus on its severely depleted cash reserves and ongoing Multikine R&D burn.
